William Richard White Sells 676 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 676 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total value of $30,338.88. Following the completion of the transaction, the chief financial officer now directly owns 61,959 shares of the company’s stock, valued at approximately $2,780,719.92. The trade was a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Akero Therapeutics Stock Down 1.6 %

Shares of AKRO opened at $44.15 on Friday. The firm has a market capitalization of $3.52 billion, a price-to-earnings ratio of -11.77 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The business’s fifty day moving average price is $42.10 and its two-hundred day moving average price is $33.84. Akero Therapeutics, Inc. has a 52 week low of $17.86 and a 52 week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). On average, analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new position in shares of Akero Therapeutics in the 4th quarter worth $41,000. Sterling Capital Management LLC boosted its position in shares of Akero Therapeutics by 764.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock worth $50,000 after purchasing an additional 1,582 shares during the last quarter. Quarry LP bought a new position in shares of Akero Therapeutics in the 4th quarter worth $83,000. Summit Investment Advisors Inc. boosted its position in shares of Akero Therapeutics by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after purchasing an additional 450 shares during the last quarter. Finally, Summit Financial Wealth Advisors LLC bought a new position in shares of Akero Therapeutics in the 3rd quarter worth $205,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Citigroup increased their target price on Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Canaccord Genuity Group increased their target price on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Bank of America upgraded Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. UBS Group increased their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Finally, HC Wainwright increased their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Monday, March 3rd. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Akero Therapeutics presently has an average rating of “Buy” and a consensus price target of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.